Presentatie - vzw farmaka asbl
Presentatie - vzw farmaka asbl
Presentatie - vzw farmaka asbl
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
β-blokkers<br />
25.Heidenreich. JAMA 1999;281:1927-36<br />
Design N/n Population Sd Interventions Outcomes Results<br />
MA<br />
(search<br />
date<br />
N=72 Angina<br />
pectoris<br />
35%<br />
Mean: 8w β-blocker vs caantagonists<br />
Angina episodes/w Mean difference=0.31 (95%CI –<br />
0.62 to 0,0) in favour of β-<br />
blockers<br />
1997)<br />
previous<br />
Nitroglycerin use/w No difference<br />
MI<br />
Time to 1 mm ST↓ No difference<br />
N=6 Mean: 5w β-blockers vs nitrates Same outcomes No difference<br />
N=12 Mean: 3w Nitrates vs ca-antagonists Same outcomes No difference<br />
Helfand M et al. Drug Class review on beta adrenergic blockers. September 2007. Oregon Evidence-based Practice Center.<br />
Design n Population Sd Interventions Outcomes Results<br />
SR 368 Angina 6m Carvedilol 100 mg vs metoprolol 200 mg -Exercise<br />
No<br />
40 pectoris 8w Pindolol 10-40 mg vs propranolol 20-240 mg parameters<br />
differences<br />
112 10w Betaxolol 20-40 mg vs propranolol 160-320 mg -Angina frequency<br />
40 6m Atenolol 50 mg vs bisoprolol 5 mg<br />
and/ or<br />
10 6m Labetolol 200 mg vs atenolol 100 mg<br />
nitroglycerine use<br />
www.<strong>farmaka</strong>.be<br />
Project<br />
Farmaka
Change language